← Feed

$AMRX

3 theses
bullish 0%neutral 0%bearish 100%
Avg return (3m)
—
Win rate (3m)
— (0 resolved)
1d3d1w1m3m6m1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 18, 4:30 PM ET
$AMRXSEC Form 4bearish
Kiely John · Amneal Pharmaceuticals, Inc. · 47d agono track record yet
Sold 50,000 @ $17.64 avg · $882,000 · 2026-08-13

Form 4: Kiely John sold AMRX

Kiely John (Director at Amneal Pharmaceuticals, Inc.) reported an open-market sale of 50,000 shares of AMRX at an average $17.64, roughly $882,000, in a Form 4 filed 2026-08-14.

At post $18.15Now $18.71+3.1% since postedas of Sep 18, 4:30 PM ET
1d—
3d+1.5%
1w-1.3%
1m-6.3%
3m—
6m—
1y—
View filing on SEC.gov →
$AMRXSEC Form 4bearish
Shah Nikita · Executive Vice President at Amneal Pharmaceuticals, Inc. · 48d agono track record yet
Sold 146,403 @ $17.51 avg · $2,563,517 · 2026-08-12

Form 4: Shah Nikita sold AMRX

Shah Nikita (Executive Vice President at Amneal Pharmaceuticals, Inc.) reported an open-market sale of 146,403 shares of AMRX at an average $17.51, roughly $2,563,517, in a Form 4 filed 2026-08-13.

At post $17.27Now $18.71+8.3% since postedas of Sep 18, 4:30 PM ET
1d+5.1%
3d+5.1%
1w+3.6%
1m-1.5%
3m—
6m—
1y—
View filing on SEC.gov →
$AMRXSEC Form 4bearish
Daly Jason B. · EVP, Chief Legal Officer at Amneal Pharmaceuticals, Inc. · 48d agono track record yet
Sold 216,613 @ $17.41 avg · $3,771,050 · 2026-08-11

Form 4: Daly Jason B. sold AMRX

Daly Jason B. (EVP, Chief Legal Officer at Amneal Pharmaceuticals, Inc.) reported an open-market sale of 216,613 shares of AMRX at an average $17.41, roughly $3,771,050, in a Form 4 filed 2026-08-13.

At post $17.27Now $18.71+8.3% since postedas of Sep 18, 4:30 PM ET
1d+5.1%
3d+5.1%
1w+3.6%
1m-1.5%
3m—
6m—
1y—
View filing on SEC.gov →

End of results.